Menu Search
Equities

Solarvest BioEnergy Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0ZJ:MUN

Solarvest BioEnergy Inc

Actions
  • Price (EUR)0.016
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 05 2023 07:26 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Solarvest BioEnergy Inc. is a Canada-based algae biologic company with several patents in organic ingredient production with global commercial product applications. The Company is focused on commercializing products utilizing its patented organic omega 3 DHA for products and processes. It is also focused on developing research and development (R&D) in protein expression, particularly as it relates to Bone Morphogenic Protein. Assessment of other areas of R&D will continue related to existing patents, including bio-hydrogen. The products produced using the Omega-3 DHA powder are produced without chemicals, solvents, and/or heavy processing that degrade the nutritional benefits. This preservation of the natural triglyceride form of the Omega-3 oils provides a pure and bioavailable health product. It offers a plant-based and sustainable product while avoiding ocean-based toxins/pollutants or residual processing solvents. It has produced Bone Morphogenetic Protein (BMP) in micro algae.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-554.52k
  • Incorporated2005
  • Employees--
  • Location
    Solarvest BioEnergy Inc439 Helmcken St.VANCOUVER V6B 2E6CanadaCAN
  • Phone+1 (604) 684-3323
  • Fax+1 (604) 239-0728
  • Websitehttps://www.solarvest.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.